ELUVIATM meta-analysis
A first-time systematic literature review comparing outcomes of the 4 most common femoropopliteal stent types in peripheral artery disease shows consistently greater Primary Patency and Target Lesion Revascularisation (TLR) outcomes for ELUVIATM Drug-Eluting Stent (DES) at both 12 and 24 months.
This meta-analysis is based on a strong set of publications, with 142 papers considered and including 52,017 patients. These findings provide valuable insights into stent performance in complex disease scenarios, helping clinicians make informed, case by case treatment decisions based on lesion characteristics and long-term outcomes.1
87%
Primary Patency at 12 months
14%
TLR at 24 months
Consistent and greater Primary Patency results
Primary Patency at 12 months
ELUVIATM DES showed a Primary Patency pooled rate of 87% at 12 months and 77.9% at 24 months, delivering higher rates compared to all other stent types.
ELUVIATM DES Primary Patency rates did not decline in long lesions (≥150mm) at 12 and 24 months and remained higher compared to all other stent types.
The lowest pooled proportions for TLR at 12 and 24 months
TLR pooled rates at 24 months
ELUVIATM DES showed the lowest pooled proportions for TLR at both 12 and 24 months in comparison to all other stent types.
Study design
Pooled analysis of 142 PubMed articles (2009-2024; n=52,017 SFA/PAD stent patients, ≥50 per study).
Evaluated primary patency, TLR, and mortality at 12 & 24 months, with subgroup analysis for lesion length.
The objective was to systematically evaluate and analyse outcomes of 4 common stent types in femoropopliteal artery disease:
1. ELUVIATM, a polymer-based paclitaxel-eluting stent (PB-PES)
2. Zilver® PTX®, a polymer-free paclitaxel-coated stent (PF-PES)
3. GORE® VIABAHN® VBX, a covered stent (CVS)
4. Self-expanding nitinol stents (SNS).
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
References
1 Holden A. Performance of stenting in femoropopliteal disease: Systemic review and meta-analysis of proportions. Charing Cross. London, UK. 23Apr2025.